RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Incidence of second primary malignancies in metastatic castration-resistant prostate cancer
Results from observational studies in three countries
Vassilev, Z. P., Gabarró, M. S., Kaye, J. A., Saltus, C. W., Riedel, O., Scholle, O., Mehtälä, J., Korhonen, P., Garbe, E., & Zong, J. (2020). Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: Results from observational studies in three countries. Future Oncology, 16(25), 1889-1901. https://doi.org/10.2217/fon-2020-0315
Aim: This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. Patients & methods: Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Data Base Sweden; and combined registry-claims data from the US Surveillance, Epidemiology and End Results-Medicare database were analyzed to obtain overall survival and incidence of SPMs in men with mCRPC. Results: SPMs occurred in 308 German (N = 2360), 273 Swedish (N = 2849) and 172 US (N = 2234) men with mCRPC. IRs of SPMs were 79.0 (95% CI: 70.4-88.4), 101.7 (95% CI: 90.3-114.5) and 59 (95% CI: 50-68) per 1000 person-years in German, Swedish and US cohorts, respectively. Conclusion: These studies report some of the first IR estimates of SPMs in men with mCRPC, providing a historical risk estimate of SPM in this patient population.